Heiser, Laura M. et al. published their research in Proceedings of the National Academy of Sciences of the United States of America in 2012 | CAS: 219580-11-7

1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Safety of 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

Subtype and pathway specific responses to anticancer compounds in breast cancer was written by Heiser, Laura M.;Sadanandam, Anguraj;Kuo, Wen-Lin;Benz, Stephen C.;Goldstein, Theodore C.;Ng, Sam;Gib, William J.;Wang, Nicholas J.;Ziyad, Safiyyah;Tong, Frances;Bayani, Nora;Hu, Zhi;Billig, Jessica I.;Dueregger, Andrea;Lewis, Sophia;Jakkula, Lakshmi;Korkola, James E.;Durinck, Steffen;Pepin, Francois;Guan, Yinghui;Purdom, Elizabeth;Neuvial, Pierre;Bengtsson, Henrik;Wood, Kenneth W.;Smith, Peter G.;Vassilev, Lyubomir T.;Hennessy, Bryan T.;Greshock, Joel;Bachman, Kurtis E.;Hardwicke, Mary Ann;Park, John W.;Marton, Laurence J.;Wolf, Denise M.;Collisson, Eric A.;Neve, Richard M.;Mills, Gordon B.;Speed, Terence P.;Feiler, Heidi S.;Wooster, Richard F.;Haussler, David;Stuart, Joshua M.;Gray, Joe W.;Spellman, Paul T.. And the article was included in Proceedings of the National Academy of Sciences of the United States of America in 2012.Safety of 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea The following contents are mentioned in the article:

Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of breast cancer cell lines mirror many of the mol. subtypes and pathways found in tumors, suggesting that treatment of cell lines with candidate therapeutic compounds can guide identification of associations between mol. subtypes, pathways, and drug response. In a test of 77 therapeutic compounds, nearly all drugs showed differential responses across these cell lines, and approx. one third showed subtype-, pathway-, and/or genomic aberration-specific responses. These observations suggest mechanisms of response and resistance and may inform efforts to develop mol. assays that predict clin. response. This study involved multiple reactions and reactants, such as 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7Safety of 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea).

1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Safety of 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia